View Article

Abstract

Transdermal drug delivery systems (TDDS) have emerged as an effective and non-invasive approach for the controlled delivery of therapeutic agents through the skin into systemic circulation. These systems offer several advantages over conventional dosage forms, including avoidance of first-pass metabolism, improved bioavailability, sustained drug release, and enhanced patient compliance. The present review provides a comprehensive overview of transdermal patches for sustained drug delivery, including their concept, components, types, and mechanisms of drug release. The structure and function of the skin as a barrier to drug permeation are also discussed. Furthermore, the advantages, limitations, and challenges associated with transdermal systems are highlighted. Recent advancements such as microneedles, iontophoresis, and sonophoresis have significantly improved drug permeation and expanded the scope of transdermal delivery for macromolecules. In addition, various therapeutic applications, including pain management, hormonal therapy, and cardiovascular treatment, are described. Future perspectives emphasize the development of smart and personalized transdermal patches integrated with advanced technologies. Overall, TDDS represents a promising strategy for sustained and controlled drug delivery in modern therapeutics.

Keywords

Transdermal patches; Sustained release; Drug delivery systems; Skin barrier; Microneedles.

Introduction

× Popup Image

Sustained release dosage forms are designed to release the drug slowly at a controlled rate, maintaining a steady drug concentration in the body over a prolonged period and minimizing side effects. The fundamental concept behind a sustained release drug delivery system is to improve patient compliance by increasing the bioavailability and therapeutic effectiveness of the drug.

1.1. Definition

A transdermal drug delivery system (TDDS) is a pharmaceutical formulation designed to deliver a required amount of medication through the skin of a patient, allowing the drug to enter the systemic circulation and produce a therapeutic effect.

    1. Approaches to sustained release drug delivery system
  1. Dissolution controlled release system
  2. Diffusion control release system
  3. Dissolution and diffusion-controlled release system
  4. Ion exchange drug complexes
  5. pH dependent formulation

A. Dissolution controlled release system

These systems are easy to prepare. Drugs formulated using this system dissolve slowly, resulting in a gradual release of the medication in the stomach and intestine. This system is mainly used for drugs that dissolve easily in water.

  1. Matrix dissolution-controlled release system

The matrix diffusion system is so called because the drug is uniformly dispersed within the matrix. When it comes into contact with the dissolution medium, the drug dissolves slowly and is released in a controlled manner. These systems are commonly prepared using waxes such as beeswax and hydrogenated castor oil, which play an important role in controlling the drug release rate. This is achieved by regulating the penetration of the dissolution fluid into the matrix, altering the porosity of the tablet, decreasing its wettability, or by the matrix itself dissolving at a slower rate. Drug release from such matrix systems generally follows first-order kinetics.

  1. Reservoir dissolution-controlled release history

In a reservoir system, drug particles are enclosed or coated using a microencapsulation method. Slow-dissolving materials such as cellulose, polyethylene glycol, and wax are used for coating. These coated drug units can be filled into capsules or compressed into tablets. The solubility and thickness of the coating determine the rate at which the drug is released or dissolved.

B. Diffusion control release system

In a diffusion-controlled drug release system, the drug first dissolves and then diffuses through a polymer membrane. This diffusion step is slow and thus controls the rate of drug release. The drug release does not follow zero-order kinetics because, over time, the drug near the surface is released first. As a result, the distance the drug must travel (diffusion path length) increases, which slows down the release rate. This occurs because the insoluble matrix gradually loses the drug over time.

C. Dissolution and diffusion-controlled release system

This system combines both dissolution and diffusion mechanisms to control drug release. Initially, the drug coating or matrix dissolves, after which the drug diffuses through the polymer barrier. This dual mechanism provides better control over the drug release profile and reduces fluctuations in drug concentration in the body. Such systems are commonly used in advanced sustained release formulations, improving therapeutic efficiency and patient compliance.

D. Ion exchange drug complexes

In ion exchange systems, the drug is bound to an ion exchange resin to form a complex. When this complex reaches the gastrointestinal tract, the drug is released by exchanging with ions such as sodium or chloride present in the fluids. The rate of drug release depends on the ionic concentration and pH of the medium. These systems are useful for taste masking and controlled release, providing a steady release of the drug over time. This method is commonly used in liquid and oral formulations.

E. pH dependent formulation

For some drugs, dissolution and absorption in the gastrointestinal tract are influenced by changes in pH. Therefore, such dosage forms are prepared with an adequate amount of buffering agents, such as salts of phosphoric, citric, or tartaric acid. These buffers help maintain the required pH as the dosage form passes through different regions of the GIT. The drug and buffer are coated with a permeable coating material, which permits the entry of aqueous fluid while preventing the disintegration or dispersion of the tablet.

2. Skin as a Barrier to drug delivery

As we know, the skin is the largest organ of the body. It plays a major role in protecting the body from various external factors and acts as a safeguard. It also helps in regulating body temperature and dermal perception. When the skin is exposed to sunlight or ultraviolet rays, a substance in the body, 7-dehydrocholesterol, is converted into vitamin D?, which helps in strengthening bones. The surface area of the skin is about 1.5–2 m² in adults and approximately 0.2 m² at birth. The skin is thicker on the soles, palms, and upper back (between the shoulders) and thinner on the penis, eyelids, and other regions.

The skin is commonly made up of three layers-

  • Epidermis
  • Dermis
  • Hypodermis

Figure 1. Structure of Skin and Transdermal Delivery Path

2.1. Epidermis

It is the outermost layer of the skin, composed of stratified keratinized squamous epithelial tissue. It contains no blood vessels or nerve endings. The cells present in this layer contain a protein called keratin. It also contains melanocytes, which are responsible for skin colour, along with other cells and components. Its area and thickness depend on the body part.

The epidermis consists of multiple layers and is composed entirely of cells. Stratum Corneum

  • Stratum Granulosum
  • Stratum Spinosum
  • Stratum Basale

Is the upper most layer of epidermis layer which is known as special layer because it keeps our body safe. It is composed of fats and proteins.

2.2. Dermis

The dermis is located beneath the epidermis, specifically below the stratum basale, and is the main layer of the skin. It is composed primarily of collagen and elastin, which provide strength and flexibility. This layer plays an important role in reducing the concentration of substances that enter the skin. It is approximately 3–5 mm thick and is thicker than the epidermis. The dermis can be considered the “mother” layer of the epidermis, as it supplies nutrients to it.

It consists of wide variety of structure

  • Blood vessel and lymph vessel
  • Sweat glands and their Ducts
  • Hair follicles, arrector pili muscles
  • Nerve endings
  • Sebaceous glands
  • Collagen and elastin fibres

The skin helps regulate body temperature through mechanisms such as heat production and heat loss, and is also involved in conditions like fever and hypothermia (body temperature below 35°C).

When medicines are applied to the skin, they first pass through a layer that behaves like a soft gel and contains mostly water. For drugs that are water-soluble, this layer offers little resistance, allowing them to pass through easily. However, for oily (lipophilic) drugs, such as those in creams or lotions, this aqueous layer can act as a barrier, making it more difficult for the drug to penetrate the skin.

2.3. Hypodermis

It is the innermost layer of the skin, also known as the subcutaneous tissue. It is composed of adipocytes (fat cells) and connective tissue. This layer plays a major role in the body by connecting the dermis to muscles and bones through specialized connective tissue called septa, which contain blood vessels, nerve cells, and collagen.

It also plays an important role in thermoregulation by preventing excessive heat loss from the body and acting as an insulator in cold environments.

When oily medicines and transdermal patches are applied, the drug must pass through these three layers to enter the bloodstream. However, in some skin treatments, the drug is intended to be absorbed only in the outermost layer, the stratum corneum, where it remains to exert its effect.

2.4. Functions of skin

  • The primary function is to work as protective barrier of the skin.
  • Its function is to thermoregulation which means homeostatic regulation of human body temperature.
  • Its works as blood reservoir because it carries 8-10% blood flow in resting adult.
  • The skin normally works as elimination of harmful substances from body called excretion.
  • Absorption (the passage of material from external environment into body cells.
  • It helps in synthesis of vitamin D.
  • It is helpful in epidermal and deep wound healing.

3. Concept of TDDS

Transdermal Drug Delivery System (TDDS) is an advanced and non-invasive drug delivery approach in which therapeutic agents are administered through the skin to achieve systemic effects. In this system, drugs are delivered across the skin layers, primarily through the stratum corneum, and enter systemic circulation at a controlled rate. The skin acts as a natural barrier, consisting of three main layers: epidermis, dermis, and hypodermis. Among these, the stratum corneum is the principal barrier to drug permeation. TDDS is designed to overcome this barrier and provide a controlled release of drugs over an extended period. The primary objectives of TDDS include improving bioavailability, avoiding first-pass hepatic metabolism, maintaining steady plasma drug concentration, and enhancing patient compliance. This system is particularly suitable for potent drugs with low molecular weight and adequate lipophilicity. Examples of drugs delivered via TDDS include nitro-glycerine, nicotine, and hormonal agents.

4. Component of Transdermal Patches

Figure 2. Six Essential Components of Multi-Layer Transdermal Patch

Transdermal patch consists of several essential components that work together to ensure efficient drug delivery:

    1. Drug (Active Pharmaceutical Ingredient)

The drug should possess suitable physicochemical properties such as low molecular weight, adequate lipophilicity, and high potency to penetrate the skin effectively.

    1. Polymer Matrix or Reservoir

This component acts as a carrier for the drug and controls its release rate. Polymers such as hydroxypropyl methylcellulose (HPMC) and ethyl cellulose are commonly used.

    1.  Permeation Enhancers

These substances enhance drug permeability by altering the structure of the stratum corneum. Examples include alcohols, dimethyl sulfoxide (DMSO), and fatty acids like oleic acid.

    1. Pressure-Sensitive Adhesive (PSA)

It ensures that the patch adheres firmly to the skin surface without causing irritation.

    1.  Backing Layer

This is the outermost protective layer that prevents drug loss and protects the patch from environmental factors such as moisture and oxygen.

    1. Release Liner

A protective layer that is removed before application of the patch to the skin.

  1. Type of Transdermal Patches

Transdermal patches are classified based on their design and drug release mechanism:

    1. Reservoir System

In this system, the drug is contained within a reservoir compartment and released through a rate-controlling membrane. It provides a constant and controlled drug release.

5.2. Matrix System

The drug is uniformly dispersed within a polymer matrix. This is the most commonly used system due to its simplicity and ease of manufacturing.

5.3. Drug-in-Adhesive System

The drug is incorporated directly into the adhesive layer. This design is thinner, more flexible, and improves patient comfort.

5.4. Micro reservoir System

This system combines features of both reservoir and matrix systems. The drug is dispersed in microscopic reservoirs within a polymer matrix, providing controlled release.

Figure 3. Comparative design of Reservoir and Matrix Transdermal Patches

  1. Advantage of transdermal patches

Transdermal drug delivery systems offer several advantages over conventional dosage forms:

  • Controlled and sustained drug release, maintaining steady plasma concentration.
  • Avoidance of first-pass metabolism, leading to improved bioavailability.
  • Improved patient compliance, as frequent dosing is not required.
  • Reduction in systemic side effects due to controlled drug input
  • Non-invasive and painless administration, eliminating the need for injections.
  • Easy termination of therapy by removing the patch.
  • Suitable for long-term therapy in chronic conditions.

7. Limitations and Challenges

Despite the numerous advantages of transdermal drug delivery systems, several limitations restrict their widespread application. One of the most common challenges associated with transdermal patches is skin irritation, which may manifest as erythema, itching, contact dermatitis, or hypersensitivity reactions at the site of application. These adverse effects are often attributed to prolonged contact with adhesives, polymers, penetration enhancers, or the drug itself.

Another significant limitation is the restricted number of suitable drug candidates for transdermal delivery. The stratum corneum acts as a highly effective barrier, permitting only drugs with specific physicochemical properties—such as low molecular weight, adequate lipophilicity, and high potency—to permeate through the skin. Consequently, large, hydrophilic, or ionic drug molecules are generally unsuitable for delivery via transdermal patches.

Additionally, dose limitation remains a critical challenge in transdermal drug delivery. Because the skin has a limited absorption capacity, transdermal patches are not appropriate for drugs that require high daily doses. Typically, only low-dose drugs can be effectively delivered through the skin, which restricts the therapeutic scope of transdermal systems for certain clinical conditions.

8. Recent Advances in Transdermal Drug Delivery Systems

Recent advancements in transdermal drug delivery systems have focused on overcoming the limitations imposed by the stratum corneum and expanding the range of drugs suitable for transdermal administration. Among these innovations, microneedles, iontophoresis, and sonophoresis have gained significant attention due to their ability to enhance drug permeation across the skin in a minimally invasive manner.

8.1 Microneedles

Microneedle-based transdermal drug delivery systems represent a promising advancement for enhancing skin permeability without causing significant pain or discomfort. Microneedles consist of microscopic needle arrays that create transient microchannels in the stratum corneum, allowing drugs to bypass the skin barrier and enter systemic circulation. These systems are particularly advantageous for the delivery of macromolecules such as peptides, proteins, and vaccines, which are otherwise unsuitable for conventional transdermal patches.

Furthermore, microneedles improve patient compliance and reduce the risk of infection compared to hypodermic injections, making them suitable for sustained  and controlled drug release applications.

8.2 Iontophoresis

Iontophoresis is an electrically assisted transdermal drug delivery technique that enhances drug permeation through the application of a mild electric current. This method facilitates the transport of charged and polar drug molecules across the skin by electro-repulsion and electro-osmosis mechanisms. Iontophoresis has been extensively explored for controlled and sustained drug delivery, particularly for drugs requiring precise dosing.

Despite its advantages, iontophoresis requires specialized devices and may cause mild skin irritation during prolonged application; however, it remains a valuable approach for improving transdermal drug flux and bioavailability.

8.3 Sonophoresis

Sonophoresis, also known as ultrasound-enhanced transdermal drug delivery, utilizes ultrasonic waves to increase skin permeability. The application of ultrasound disrupts the lipid structure of the stratum corneum through cavitation effects, thereby facilitating enhanced drug diffusion across the skin. Sonophoresis is particularly effective for improving the transdermal delivery of both low and high molecular weight drugs.

This technique has shown promising results in combination with transdermal patches for sustained drug release; however, careful control of ultrasound intensity is essential to prevent skin damage.

9. Applications of Transdermal Patches

Transdermal patches have found wide clinical applications due to their ability to provide sustained and controlled drug release, improve patient compliance, and avoid first-pass metabolism. They are particularly useful in the management of chronic conditions where long-term therapy is required. Major therapeutic applications of transdermal patches include pain management, hormonal therapy, and cardiovascular disorders.

9.1 Pain Management

Transdermal patches are extensively used in the management of both acute and chronic pain conditions. Drugs such as fentanyl, buprenorphine, diclofenac, and lidocaine are commonly administered via transdermal patches to achieve sustained analgesic effects. This route provides continuous drug delivery over an extended period, thereby reducing fluctuations in plasma drug concentration and Minimizing dosing frequency.

Transdermal analgesic patches are especially beneficial in patients suffering from chronic pain, arthritis, and postoperative pain, as they improve patient compliance and reduce gastrointestinal side effects associated with oral analgesics.

9.2 Hormonal Therapy

Hormonal therapy represents one of the most successful clinical applications of transdermal drug delivery systems. Transdermal patches are widely used for hormone replacement therapy (HRT), contraception, and management of menopausal symptoms. Estrogen, progesterone, testosterone, and combined hormonal formulations are effectively delivered through the skin using transdermal patches.

This route offers consistent hormone levels, reduced hepatic first-pass metabolism, and a lower risk of systemic side effects compared to oral formulations. Consequently, transdermal hormonal patches are preferred for long-term therapy in many patients.

9.3 Cardiovascular Drugs

Transdermal patches are also employed in the treatment of cardiovascular diseases, particularly for the management of angina pectoris and hypertension. Nitro-glycerine and clonidine transdermal patches are commonly used to provide sustained drug delivery and prolonged therapeutic action.

The transdermal route ensures steady plasma drug levels, reduces dosing frequency, and improves adherence to therapy in patients requiring long-term cardiovascular treatment. Additionally, bypassing gastrointestinal metabolism enhances the bioavailability of certain cardiovascular drugs.

10. Future Prospectives

Smart transdermal patches represent the next generation of transdermal drug delivery systems. These advanced patches are designed to respond to physiological or external stimuli such as temperature, pH, glucose level, or electrical signals. The integration of sensors, microelectronics, and responsive polymers allows controlled and on-demand drug release, improving therapeutic efficacy and patient safety. Smart patches can also monitor patient parameters in real time and adjust drug delivery accordingly, making them highly suitable for chronic diseases requiring long-term treatment. With continuous technological advancements, smart transdermal patches are expected to significantly enhance patient compliance and personalized therapy outcomes.

Personalized drug delivery through transdermal patches is an emerging approach aimed at tailoring drug dose and release profiles according to individual patient needs. Factors such as age, skin type, disease severity, and metabolic rate can influence drug absorption, and personalized transdermal systems help address these variations. Advances in digital health technologies, wearable devices, and data-driven dose optimization are enabling the development of customized transdermal patches. In the future, personalized transdermal drug delivery is expected to reduce adverse effects, improve treatment effectiveness, and support precision medicine, especially in the management of chronic and lifestyle-related disorders.

CONCLUSION

Transdermal drug delivery systems have gained significant attention as a reliable and patient-friendly approach for sustained drug administration. By bypassing first-pass metabolism and providing controlled drug release, transdermal patches improve therapeutic efficacy and patient compliance. Despite their advantages, limitations such as skin irritation, restricted drug selection, and dose constraints remain challenges in their widespread application. However, recent technological advancements, including microneedles, iontophoresis, and sonophoresis, have opened new possibilities for enhancing drug permeation and expanding the range of deliverable drugs. Furthermore, the development of smart and personalized transdermal patches is expected to revolutionize drug delivery by enabling real-time monitoring and controlled drug release based on patient-specific needs. In conclusion, transdermal drug delivery systems hold great potential in the future of pharmaceutical research and clinical therapeutics, particularly for chronic disease management and precision medicine.

REFERENCES

  1. Priyanka Prajapati, Dilip Agarwal, Gaurav bhaduka. A brief overview of sustained release truck delivery system, JAPTR, 2022, page no. 7-8
  2. Nadia Sheikh, Richa Srivastava. A review of transdermal drug delivery patches, IJCED 2024, page – 1
  3. Allen, L. V., Popovich, N. G., & Ansel, H. C. (2013). Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems (10th ed.). Lippincott Williams & Wilkins.
  4. Chien, Y. W. (1992). Novel Drug Delivery Systems (2nd ed.). Marcel Dekker, Inc.
  5. Guy, R. H., & Hadgraft, J. (2003). Transdermal Drug Delivery (2nd ed.). CRC Press.
  6. Jain, N. K. (2008). Controlled and Novel Drug Delivery. CBS Publishers & Distributors.
  7. Khar, R. K., Vyas, S. P., Ahmad, F. J., & Jain, G. K. (2014). Controlled Drug Delivery: Concepts and Advances. Vallabh Prakashan.
  8. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261–1268.
  9. Brown, M. B., Martin, G. P., Jones, S. A., & Akomeah, F. K. (2006). Dermal and transdermal drug delivery systems: Current and future prospects. Drug Delivery, 13(3), 175–187.
  10.  Shaikh N, Srivastava R. A review on transdermal drug delivery through patches. IP Indian Journal of Clinical and Experimental Dermatology. 2024;10(2):113–121.
  11.  Kharia A, Gilhotra R, Singhai AK. Overview of transdermal medicated patches with research updates. Journal of Drug Delivery and Therapeutics. 2019;9(3-s):1094–1102.
  12.  Prausnitz MR, Langer R. Transdermal drug delivery. Advanced Drug Delivery Reviews. 2008;60(17):206–212.
  13. Reddy VS. Recent advances in transdermal drug delivery systems. Asian Journal of Pharmaceutics. 2025;19(2).
  14. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Journal of Controlled Release. 2004;97(2):193–205.
  15. Banga AK. Electrically assisted transdermal and topical drug delivery. International Journal of Pharmaceutics. 2011;421(1):1–12.
  16. Mitragotri S, Kost J. Low-frequency sonophoresis: a review. Advanced Drug Delivery Reviews. 2004;56(5):589–601.
  17. Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery. Journal of Drug Delivery Science and Technology. 2011;21(4):297–307.
  18. Trescot AM, et al. Opioid pharmacology. Journal of Pain Research. 2008;1:1–10.
  19.  Kalia YN, Guy RH. Transdermal drug delivery of analgesics. Journal of Controlled Release. 2001;74(1–3):1–9.
  20. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. International Journal of Pharmaceutics. 2005;297(1–2):1–9.
  21. Banga AK. Transdermal and intradermal delivery of hormones. AAPS Pharm SciTech. 2015;16(4):802–809.
  22. Sharma PK, et al. Transdermal drug delivery system: formulation and evaluation. Asian Journal of Pharmaceutics. 2011;5(2):78–84.
  23. Hadgraft J, Lane ME. Passive transdermal drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics. 2005;59(3):413–422.
  24. Banga, A. K. (2015) Transdermal and Intradermal Drug Delivery: Critical Factors and Advances CRC Press.
  25. Santoro, M., et al. (2020) Smart drug delivery systems for transdermal applications Advanced Drug Delivery Reviews, 154–155, 21–38.
  26. Langer, R. (2012) Drug delivery and targeting Nature, 392, 5–10.
  27. Park, K. (2014) Personalized medicine: Recent advances and future prospects Journal of Controlled Release, 190, 3–8.
  28. Mitragotri, S., et al. (2011) Overcoming the skin barrier: The future of transdermal drug delivery Nature Reviews Drug Discovery, 10, 697–713.    

Reference

  1. Priyanka Prajapati, Dilip Agarwal, Gaurav bhaduka. A brief overview of sustained release truck delivery system, JAPTR, 2022, page no. 7-8
  2. Nadia Sheikh, Richa Srivastava. A review of transdermal drug delivery patches, IJCED 2024, page – 1
  3. Allen, L. V., Popovich, N. G., & Ansel, H. C. (2013). Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems (10th ed.). Lippincott Williams & Wilkins.
  4. Chien, Y. W. (1992). Novel Drug Delivery Systems (2nd ed.). Marcel Dekker, Inc.
  5. Guy, R. H., & Hadgraft, J. (2003). Transdermal Drug Delivery (2nd ed.). CRC Press.
  6. Jain, N. K. (2008). Controlled and Novel Drug Delivery. CBS Publishers & Distributors.
  7. Khar, R. K., Vyas, S. P., Ahmad, F. J., & Jain, G. K. (2014). Controlled Drug Delivery: Concepts and Advances. Vallabh Prakashan.
  8. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261–1268.
  9. Brown, M. B., Martin, G. P., Jones, S. A., & Akomeah, F. K. (2006). Dermal and transdermal drug delivery systems: Current and future prospects. Drug Delivery, 13(3), 175–187.
  10.  Shaikh N, Srivastava R. A review on transdermal drug delivery through patches. IP Indian Journal of Clinical and Experimental Dermatology. 2024;10(2):113–121.
  11.  Kharia A, Gilhotra R, Singhai AK. Overview of transdermal medicated patches with research updates. Journal of Drug Delivery and Therapeutics. 2019;9(3-s):1094–1102.
  12.  Prausnitz MR, Langer R. Transdermal drug delivery. Advanced Drug Delivery Reviews. 2008;60(17):206–212.
  13. Reddy VS. Recent advances in transdermal drug delivery systems. Asian Journal of Pharmaceutics. 2025;19(2).
  14. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Journal of Controlled Release. 2004;97(2):193–205.
  15. Banga AK. Electrically assisted transdermal and topical drug delivery. International Journal of Pharmaceutics. 2011;421(1):1–12.
  16. Mitragotri S, Kost J. Low-frequency sonophoresis: a review. Advanced Drug Delivery Reviews. 2004;56(5):589–601.
  17. Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery. Journal of Drug Delivery Science and Technology. 2011;21(4):297–307.
  18. Trescot AM, et al. Opioid pharmacology. Journal of Pain Research. 2008;1:1–10.
  19.  Kalia YN, Guy RH. Transdermal drug delivery of analgesics. Journal of Controlled Release. 2001;74(1–3):1–9.
  20. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. International Journal of Pharmaceutics. 2005;297(1–2):1–9.
  21. Banga AK. Transdermal and intradermal delivery of hormones. AAPS Pharm SciTech. 2015;16(4):802–809.
  22. Sharma PK, et al. Transdermal drug delivery system: formulation and evaluation. Asian Journal of Pharmaceutics. 2011;5(2):78–84.
  23. Hadgraft J, Lane ME. Passive transdermal drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics. 2005;59(3):413–422.
  24. Banga, A. K. (2015) Transdermal and Intradermal Drug Delivery: Critical Factors and Advances CRC Press.
  25. Santoro, M., et al. (2020) Smart drug delivery systems for transdermal applications Advanced Drug Delivery Reviews, 154–155, 21–38.
  26. Langer, R. (2012) Drug delivery and targeting Nature, 392, 5–10.
  27. Park, K. (2014) Personalized medicine: Recent advances and future prospects Journal of Controlled Release, 190, 3–8.
  28. Mitragotri, S., et al. (2011) Overcoming the skin barrier: The future of transdermal drug delivery Nature Reviews Drug Discovery, 10, 697–713.    

Photo
Shailender Kumar
Corresponding author

Assistant Professor, Dilip Kishore Mehrotra Institute of Pharmacy, Sitapur, Uttar Pradesh, India

Photo
Saurabh Mishra
Co-author

Dilip Kishore Mehrotra Institute of Pharmacy, Sitapur, Uttar Pradesh, India

Photo
Mahak Verma
Co-author

Dilip Kishore Mehrotra Institute of Pharmacy, Sitapur, Uttar Pradesh, India

Photo
Kanishaka Singh
Co-author

Dilip Kishore Mehrotra Institute of Pharmacy, Sitapur, Uttar Pradesh, India

Photo
Ojaswi Singh
Co-author

Dilip Kishore Mehrotra Institute of Pharmacy, Sitapur, Uttar Pradesh, India

Photo
Sachin Kumar
Co-author

Dilip Kishore Mehrotra Institute of Pharmacy, Sitapur, Uttar Pradesh, India

Shailender Kumar, Saurabh Mishra, Mahak Verma, Kanishaka Singh, Ojaswi Singh, Sachin Kumar, Transdermal Patches for Sustained Drug Release: A Comprehensive Review, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 5557-5567. https://doi.org/10.5281/zenodo.20327015

More related articles
Nanotechnology-Enabled Strategies for Sustained Re...
Darshan Jadhav, Rishikesh Bachhav, Khanderao Jadhav, Sheetal Gond...
A Novel Formulation and Evaluation of Polyherbal G...
Kanchan Jamkar, Dr Ramesh Ingole, Rodge Mohini, Wakte Sneha, Kad...
Agro-Waste Valorization of Pomegranate Peel: Isolation of Ellagic Acid and Devel...
Rasika Tilekar, Pramod Ingale, Swadeep Karpe, Atharva Naikare, Bhagyashri Gandhile...
A Critical Review on Characterization Methods of SMEDDS: Droplet Dynamics, Therm...
Yash Patel, Nitin G. Haswani, K. M. Agrawal, Amod Patil, Pritam Jain, Mahesh Bhagwat, Pranjali Linga...
More related articles
Nanotechnology-Enabled Strategies for Sustained Release of Poorly Soluble Drugs...
Darshan Jadhav, Rishikesh Bachhav, Khanderao Jadhav, Sheetal Gondkar...
A Novel Formulation and Evaluation of Polyherbal Gel Body Wash...
Kanchan Jamkar, Dr Ramesh Ingole, Rodge Mohini, Wakte Sneha, Kadam Priti, Khune Jayshree, Raut Sidh...
Nanotechnology-Enabled Strategies for Sustained Release of Poorly Soluble Drugs...
Darshan Jadhav, Rishikesh Bachhav, Khanderao Jadhav, Sheetal Gondkar...
A Novel Formulation and Evaluation of Polyherbal Gel Body Wash...
Kanchan Jamkar, Dr Ramesh Ingole, Rodge Mohini, Wakte Sneha, Kadam Priti, Khune Jayshree, Raut Sidh...